서브메뉴
검색
상세정보
Impact of Milk Fat Globule Membrane on Cardiometabolic Risk, Gut Barrier Health, and Gut Microbiota in Adults With Metabolic Syndrome.
Impact of Milk Fat Globule Membrane on Cardiometabolic Risk, Gut Barrier Health, and Gut Microbiota in Adults With Metabolic Syndrome.
상세정보
- 자료유형
- 학위논문(국외)
- 기본표목-개인명
- 표제와 책임표시사항
- Impact of Milk Fat Globule Membrane on Cardiometabolic Risk, Gut Barrier Health, and Gut Microbiota in Adults With Metabolic Syndrome.
- 발행, 배포, 간사 사항
- 발행, 배포, 간사 사항
- 형태사항
- 208 p.
- 일반주기
- Source: Dissertations Abstracts International, Volume: 86-11, Section: B.
- 일반주기
- Advisor: Bruno, Richard S.
- 학위논문주기
- Thesis (Ph.D.)--The Ohio State University, 2024.
- 요약 등 주기
- 요약Metabolic syndrome (MetS) is a growing global health concern associated with significant cardiometabolic risk, highlighting the need for effective dietary strategies. Full-fat dairy products are associated with a lower prevalence of MetS, though their health effects remain debated. Milk fat globule membrane (MFGM), a component of full-fat dairy, has demonstrated anti-inflammatory and anti-microbial properties in preclinical studies and infants but has not been studied in adults with impaired cardiovascular health. Therefore, for this dissertation, the central hypothesis was that an MFGM-enriched beverage (MEB) would improve cardiometabolic risk factors (lipids, postprandial responses) and biomarkers of gut health (serum endotoxin concentration, intestinal permeability, and short-chain and branched-chain fatty acids). To test this hypothesis, we conducted a double-blind, randomized controlled crossover trial in adults with MetS (n = 24). Participants received MEB (3 servings/day) or a soy phospholipid comparator beverage (COMP) for two weeks while following a prescribed eucaloric diet. The results from Chapter 3 demonstrated high participant compliance with no adverse effects or dietary differences between trials. MEB largely did not affect postprandial excursions or fasting biomarkers of cardiometabolic health. However, there was noticeable inter-individual variability across all biomarkers, suggesting that a more tailored approach is needed to determine if some individuals might benefit more from MEB. To investigate this further in Chapter 4, we examined the fecal microbiota of participants to determine if changes in the microbiota, known to be heterogeneous in response to diet, could be implicated in the health benefits of MEB. Indeed, the relative abundance of several beneficial bacteria was higher in the MEB group compared to the COMP group, and several bacterial populations were favorably associated with biomarkers of endotoxemia and glucose tolerance. This suggests that a longer-term study might demonstrate that changes in gut microbiota leads to favorable systemic effects. Further, individuals with a greater shift in their microbiota, measured by β-diversity, had a greater enrichment of Akkermansia and functions related to sphingolipid metabolism compared to those with less change in β-diversity. Those with detectable levels of Akkermansia also had lower serum endotoxin concentrations and improved glucose tolerance, effects not observed in the COMP group. These exploratory findings suggest that the health benefits of MFGM is mediated by the gut microbiota. Further hypothesis-driven studies are needed to confirm if individuals with higher levels of Akkermansia are more likely to benefit from MEB. Thus, the outcomes from this dissertation provide novel evidence that: 1) a two-week controlled administration of MEB in individuals with MetS does not affect gut barrier function, glucose tolerance, or other cardiometabolic health biomarkers, which contradicts observational evidence suggesting that full-fat milk heightens cardiometabolic risk; and 2) for the first time in an adult population with MetS, MFGM favorably modulates the gut microbiota.
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 비통제 색인어
- 비통제 색인어
- 비통제 색인어
- 비통제 색인어
- 부출표목-단체명
- 기본자료저록
- Dissertations Abstracts International. 86-11B.
- 전자적 위치 및 접속
- 원문정보보기
MARC
008260219s2024 us ||||||||||||||c||eng d■001000017358218
■00520260202103701
■006m o d
■007cr#unu||||||||
■020 ▼a9798314896716
■035 ▼a(MiAaPQ)AAI32112145
■035 ▼a(MiAaPQ)OhioLINKosu173586435430589
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a641
■1001 ▼aPokala, Avinash.
■24510▼aImpact of Milk Fat Globule Membrane on Cardiometabolic Risk, Gut Barrier Health, and Gut Microbiota in Adults With Metabolic Syndrome.
■260 ▼a[S.l.]▼bThe Ohio State University. ▼c2024
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2024
■300 ▼a208 p.
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-11, Section: B.
■500 ▼aAdvisor: Bruno, Richard S.
■5021 ▼aThesis (Ph.D.)--The Ohio State University, 2024.
■520 ▼aMetabolic syndrome (MetS) is a growing global health concern associated with significant cardiometabolic risk, highlighting the need for effective dietary strategies. Full-fat dairy products are associated with a lower prevalence of MetS, though their health effects remain debated. Milk fat globule membrane (MFGM), a component of full-fat dairy, has demonstrated anti-inflammatory and anti-microbial properties in preclinical studies and infants but has not been studied in adults with impaired cardiovascular health. Therefore, for this dissertation, the central hypothesis was that an MFGM-enriched beverage (MEB) would improve cardiometabolic risk factors (lipids, postprandial responses) and biomarkers of gut health (serum endotoxin concentration, intestinal permeability, and short-chain and branched-chain fatty acids). To test this hypothesis, we conducted a double-blind, randomized controlled crossover trial in adults with MetS (n = 24). Participants received MEB (3 servings/day) or a soy phospholipid comparator beverage (COMP) for two weeks while following a prescribed eucaloric diet. The results from Chapter 3 demonstrated high participant compliance with no adverse effects or dietary differences between trials. MEB largely did not affect postprandial excursions or fasting biomarkers of cardiometabolic health. However, there was noticeable inter-individual variability across all biomarkers, suggesting that a more tailored approach is needed to determine if some individuals might benefit more from MEB. To investigate this further in Chapter 4, we examined the fecal microbiota of participants to determine if changes in the microbiota, known to be heterogeneous in response to diet, could be implicated in the health benefits of MEB. Indeed, the relative abundance of several beneficial bacteria was higher in the MEB group compared to the COMP group, and several bacterial populations were favorably associated with biomarkers of endotoxemia and glucose tolerance. This suggests that a longer-term study might demonstrate that changes in gut microbiota leads to favorable systemic effects. Further, individuals with a greater shift in their microbiota, measured by β-diversity, had a greater enrichment of Akkermansia and functions related to sphingolipid metabolism compared to those with less change in β-diversity. Those with detectable levels of Akkermansia also had lower serum endotoxin concentrations and improved glucose tolerance, effects not observed in the COMP group. These exploratory findings suggest that the health benefits of MFGM is mediated by the gut microbiota. Further hypothesis-driven studies are needed to confirm if individuals with higher levels of Akkermansia are more likely to benefit from MEB. Thus, the outcomes from this dissertation provide novel evidence that: 1) a two-week controlled administration of MEB in individuals with MetS does not affect gut barrier function, glucose tolerance, or other cardiometabolic health biomarkers, which contradicts observational evidence suggesting that full-fat milk heightens cardiometabolic risk; and 2) for the first time in an adult population with MetS, MFGM favorably modulates the gut microbiota.
■590 ▼aSchool code: 0168.
■650 4▼aNutrition.
■650 4▼aMicrobiology.
■650 4▼aPublic health.
■653 ▼aMetabolic syndrome
■653 ▼aGlobal health
■653 ▼aMicrobiota
■653 ▼aCardiometabolic risk
■690 ▼a0570
■690 ▼a0410
■690 ▼a0573
■71020▼aThe Ohio State University▼bOhio State University Nutrition.
■7730 ▼tDissertations Abstracts International▼g86-11B.
■790 ▼a0168
■791 ▼aPh.D.
■792 ▼a2024
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17358218▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
